Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kyowa Kirin and Kura Oncology announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial for ziftomenib, an oral menin inhibitor for treating relapsed or refractory NPM1-mutated acute myeloid leukemia. Ziftomenib was previously approved by the FDA in November 2025 under the brand name KOMZIFTI. Following trial completion, Kyowa Kirin plans to file for regulatory approval in Japan.

04/24/2026, 8:00 AM • GlobeNewswire

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology announced preliminary data from the FIT-001 clinical trial showing that darlifarnib combined with cabozantinib demonstrated a 44% objective response rate and 94% disease control rate in cabozantinib-pretreated clear cell renal cell carcinoma patients. The combination showed tumor shrinkage in 75% of patients with durable treatment durations up to 56 weeks and a manageable safety profile, suggesting potential to overcome resistance to prior cabozantinib therapy.

04/17/2026, 6:00 AM • GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology granted nonstatutory stock options to purchase 153,750 shares to six new employees on April 1, 2026, with an exercise price of $8.34 per share. The options vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.

04/03/2026, 7:30 AM • GlobeNewswire

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.

12/04/2025, 12:20 PM • Benzinga

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin announced FDA approval of KOMZIFTI, a once-daily oral menin inhibitor for relapsed/refractory NPM1-mutated AML, which has been added to NCCN Guidelines as a recommended treatment option.

11/25/2025, 5:16 PM • GlobeNewswire

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Kura Oncology presented preliminary clinical data at ESMO 2025 demonstrating promising results for its farnesyl transferase inhibitor (FTI) programs, showing potential in combination therapies for treating various cancer types with encouraging response rates.

10/18/2025, 3:23 AM • GlobeNewswire

Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications

Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.

10/10/2025, 4:54 AM • GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

09/29/2025, 1:35 PM • Benzinga

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Kura Oncology and Kyowa Kirin published pivotal clinical trial results for ziftomenib, an investigational menin inhibitor targeting NPM1-mutated acute myeloid leukemia (AML), showing promising response rates and potential for FDA approval in November 2025.

09/25/2025, 5:18 PM • Benzinga